Date | Time | Source | Headline | Symbol | Company |
09/14/2024 | 5:18AM | PR Newswire (US) | Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia | | |
09/14/2024 | 5:00AM | PR Newswire (US) | Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines | NASDAQ:NUVL | Nuvalent Inc |
09/14/2024 | 4:15AM | Business Wire | Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer | NYSE:PFE | Pfizer Inc |
09/14/2024 | 4:15AM | GlobeNewswire Inc. | Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 | NASDAQ:CGEM | Cullinan Therapeutics Inc |
09/14/2024 | 4:06AM | PR Newswire (US) | Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 | | |
09/14/2024 | 4:00AM | Business Wire | SVTA Announces New Board Officers | | |
09/14/2024 | 4:00AM | Business Wire | Irdeto Partners with Bitmovin to Deliver Industry-Leading Secure Low-Latency Streaming with Unmatched User Experience | | |
09/14/2024 | 4:00AM | PR Newswire (US) | Inside Flagright: Our Approach to Hiring and Team Growth | | |
09/14/2024 | 3:59AM | Business Wire | SCFがニューパーク・フルード・システムズを買収 | NYSE:NR | Newpark Resources Inc |
09/14/2024 | 3:30AM | GlobeNewswire Inc. | Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 | NASDAQ:BDTX | Black Diamond Therapeutics Inc |
09/14/2024 | 3:15AM | Alliance News | US President Biden, UK PM Starmer put off Ukraine missiles decision | | |
09/14/2024 | 3:15AM | Business Wire | KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma | NYSE:MRK | Merck and Co Inc |
09/14/2024 | 3:14AM | Alliance News | Harris, Trump campaign in US battlegrounds as migrant row intensifies | | |
09/14/2024 | 3:10AM | Alliance News | TOP NEWS: China retail sales, industrial production slow in August | | |
09/14/2024 | 3:10AM | PR Newswire (US) | RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer | NYSE:JNJ | Johnson and Johnson |
09/14/2024 | 3:10AM | GlobeNewswire Inc. | Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis | NASDAQ:ACRV | Acrivon Therapeutics Inc |
09/14/2024 | 3:09AM | Alliance News | China says German ships in Taiwan Strait "increase security risks" | | |
09/14/2024 | 3:09AM | Alliance News | UK PM Starmer says serious and ambitious about reset with EU | | |
09/14/2024 | 3:05AM | Business Wire | Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 | NYSE:NUVB | Panacea Acquisition Corp |
09/14/2024 | 3:05AM | GlobeNewswire Inc. | Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments | EU:TNG | Transgene SA |
09/14/2024 | 3:01AM | GlobeNewswire Inc. | NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 | NASDAQ:NCNA | NuCana PLC |
09/14/2024 | 3:00AM | GlobeNewswire Inc. | Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer | NASDAQ:IMCR | Immunocore Holdings PLC |
09/14/2024 | 3:00AM | GlobeNewswire Inc. | Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 | NASDAQ:STRO | Sutro Biopharma Inc |
09/14/2024 | 3:00AM | GlobeNewswire Inc. | Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors | LSE:AVCT | Avacta Group Plc |
09/14/2024 | 3:00AM | Business Wire | Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 | NASDAQ:BCYC | Bicycle Therapeutics PLC |
09/14/2024 | 2:39AM | Business Wire | Deuxième conférence sur l'échange de cultures agricoles et l'apprentissage mutuel dans le monde « FROM ZIQUEJIE TERRACES TO THE WORLD » | | |
09/14/2024 | 2:30AM | GlobeNewswire Inc. | IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer | NASDAQ:IOBT | IO Biotech Inc |
09/14/2024 | 2:30AM | GlobeNewswire Inc. | iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients | NASDAQ:ITOS | iTeos Therapeutics Inc |
09/14/2024 | 2:05AM | Business Wire | SCF übernimmt Newpark Fluids Systems | NYSE:NR | Newpark Resources Inc |
09/14/2024 | 2:05AM | Business Wire | SCF acquiert Newpark Fluids Systems | NYSE:NR | Newpark Resources Inc |